Inclusion Criteria:

          1. Woman, ≥18 years old;

          2. Histologically confirmed locally recurrent (unresectable) or metastatic breast cancer;

          3. Triple negative breast cancer:

             Estrogen receptor (ER)-negative and Progesterone receptor (PgR)-negative, as defined
             by a <10 % tumor stained cells by immunohistochemistry (IHC); HER2 negative status
             (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), confirmed
             centrally before inclusion with FFPE tissue from the primary tumour;

          4. Androgen receptor (AR)-positive, as defined centrally by a ≥ 10% tumor stained cells
             by IHC Note: AR assessment by local pathologist before inclusion is not mandatory;

          5. Patients with a relapse or progressive disease should be chemotherapy naïve or have
             received a maximum of one line of chemotherapy for advanced disease (providing they
             are not presenting with life-threatening metastasis); patients could have received
             adjuvant or neo-adjuvant therapy;

          6. In the exceptional situation of pre-menopausal patient, the addition of a LHRH analog
             is recommended (androgens might act as an estrogen antagonist in premenopausal
             patients);

          7. Presence of measurable or evaluable disease according to response evaluation criteria
             in solid tumors version 1.1 (RECIST v1.1)

          8. Eastern cooperative oncology group (ECOG) ≤1;

          9. Normal hematological function: Absolute neutrophile count (ANC) ≥1,500/mm³; platelets
             count ≥100,000/mm³; hemoglobin >10 g/dL; Note: subject must not have received any
             growth factor within 4 weeks or blood transfusion within 7 days of the hematology
             laboratory sample obtained at screening)

         10. Normal hepatic function: total bilirubin ≤ 1.5 upper normal limit (UNL) unless this
             increase is due to a known Gilbert's disease; aspartate aminotransferase (ASAT) and
             alanine aminotransferase (ALAT) ≤2.5 UNL (or ≤5 UNL in case of hepatic metastasis);

         11. Creatinine clearance (MDRD formula) ≥50 mL/min;

         12. Systolic blood pressure (BP) <160 mm Hg and diastolic BP <95 mm Hg, as documented on
             day of registration/consent (Hypertension allowed provided it is currently
             controlled);

         13. Cardiac ejection fraction ≥50% measured by multigated acquisition (MUGA) or
             echocardiography (ECHO) done within 4 weeks before inclusion;

         14. For premenopausal patients, patient agreeing to use effective contraception during and
             for ≥6 months after completion of study treatment;

         15. Patient able to comply with the protocol;

         16. Patient must have signed a written informed consent form prior to any study specific
             procedures;

         17. Patient must be affiliated to a Social Health Insurance.

        Exclusion Criteria:

          1. HER2-positive status (positivity defined as IHC3+ and/or FISH amplification ≥2);

          2. Other concurrent malignancies, except adequately treated cone-biopsied in situ
             carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin; patients
             who have undergone potentially curative therapy for a prior malignancy are eligible
             provided there is no evidence of disease for ≥5 years and patient is deemed to be at
             low risk for recurrence;

          3. Active brain metastases or leptomeningeal disease; history of brain metastases allowed
             provided lesions are stable for at least 3 months as documented by head CT scan or
             Magnetic resonance Imaging (MRI) of the brain;

          4. Non-malignant systemic disease, including active infection or concurrent serious
             illness that would make the patient a high medical risk;

          5. Significant cardiovascular disease, including any of the following:

               1. NYHA class III-IV congestive heart failure

               2. Stroke, unstable angina pectoris or myocardial infarction within the past 6
                  months

               3. Severe valvular heart disease

               4. Ventricular arrhythmia requiring treatment;

          6. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption should not be included;

          7. Persistent toxicities grade ≥2 from any cause, except chemotherapy-induced alopecia
             and grade 2 peripheral neuropathy;

          8. Any gastrointestinal disorder interfering with absorption of the study drug;

          9. Difficulties with swallowing tablets;

         10. An active viral hepatitis, known human immunodeficiency virus infection with
             detectable viral load, or chronic liver disease requiring treatment;

         11. PREVIOUS TREATMENT IN THE METASTATIC SETTING: Previous treatment with: capecitabine
             (MET SETTING), first generation (bicalutamide) or second-generation AR inhibitors
             (enzalutamide, ARN-509, darolutamide) or other investigational AR inhibitors CYP17
             enzyme inhibitor such as abiraterone (capecitabine in the adjuvant setting is allowed
             provided the last administration was at least ≥12 months prior to study entry)

         12. Patients with known deficit of dihydropyrimidine dehydrogenase (DPD) activity; or in
             case of hypersensitivity to capecitabine or to any of its excipients or to
             fluorouracil;

         13. Prior anticancer therapy within the last 3 weeks including radiotherapy, endocrine
             therapy, immunotherapy; chemotherapy (6 weeks for nitrosoureas and mitomycin C), or
             other investigational agents; concurrent palliative radiotherapy is allowed;

         14. Concurrent enrolment in another clinical trial in which investigational therapies are
             administered;

         15. Pregnant women, women who are likely to become pregnant or are breast-feeding;

         16. Patients with any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule. Those
             conditions should be discussed with the patient before registration in the trial;

         17. Patients with history of non-compliance to medical regimens or unwilling or unable to
             comply with the protocol;

         18. Individual deprived of liberty or placed under the authority of a tutor.